Injectable L-Carnitine bypasses the severe bioavailability limitations of oral carnitine supplementation. Oral L-Carnitine has only 5-18% absorption, meaning most of a 2-3g oral dose is wasted and metabolized by gut bacteria into TMAO (a cardiovascular risk marker). Injectable L-Carnitine delivers 100% bioavailability directly into the bloodstream, allowing meaningful increases in muscle carnitine content. L-Carnitine plays a critical role in fatty acid transport into mitochondria for beta-oxidation, androgen receptor upregulation, and exercise recovery. For AAS users, injectable L-Carnitine is particularly valued for its ability to increase androgen receptor density, potentially amplifying the effects of exogenous testosterone and other androgens.
Notes
L-Carnitine was first isolated from meat extract in 1905. It is conditionally essential — the body synthesizes it from lysine and methionine, but synthesis may not keep pace with demand during intense exercise. The injectable form solves the oral bioavailability problem that plagued carnitine supplementation for decades. The androgen receptor upregulation data comes primarily from research by Kraemer et al. showing increased AR content in muscle following L-Carnitine L-Tartrate supplementation, though the injectable route provides far superior tissue delivery.
L-Carnitine (as L-carnitine or acetyl-L-carnitine) is an endogenous amino acid derivative essential for mitochondrial fatty acid transport. It acts as a shuttle molecule: carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane conjugates long-chain fatty acyl-CoA with carnitine to form acylcarnitine, which crosses the inner membrane via carnitine-acylcarnitine translocase. CPT-II then regenerates fatty acyl-CoA inside the mitochondria for beta-oxidation. Beyond fat metabolism, L-Carnitine has been shown to upregulate androgen receptor (AR) expression in muscle tissue, increase AR density, and reduce exercise-induced muscle damage by decreasing markers of purine catabolism and free radical formation. The AR upregulation mechanism is mediated by carnitine's role in reducing oxidative stress at the receptor level and potentially improving AR protein stability.
Injectable L-Carnitine achieves 100% bioavailability (vs. 5-18% oral). Peak plasma concentration within 30-60 minutes post-injection. Distributed widely in tissues with highest concentrations in skeletal muscle (95% of body stores), heart, kidney, and liver. Not metabolized — excreted unchanged by the kidneys. Plasma half-life is 2-4 hours, but muscle tissue carnitine levels remain elevated for much longer. Muscle carnitine loading with injectable carnitine is significantly faster and more complete than oral supplementation. Renal clearance is the primary elimination route.
Typical Dose
Fat loss/performance: 500-700mg daily or 5-6 days per week. Androgen receptor upregulation: 500-700mg daily, ideally timed around training. Loading phase (optional): 700mg daily for 2-4 weeks, then maintenance at 500mg 5x/week.
Frequency
Daily injection (5-7 days per week) for optimal tissue saturation. Some users inject once daily pre-workout; others split AM/PM.
Administration
Subcutaneous or intramuscular injection. SubQ in the abdominal area is most common. IM into larger muscle groups is also used. Rotate injection sites to prevent lipodystrophy.
Half-Life
2-4 hours in plasma (but tissue retention and functional effects persist much longer)
Contraindications